What was Foresee Pharmaceuticals Co., Ltd.’s price range in the past 12 months?
Foresee Pharmaceuticals Co., Ltd. lowest stock price was TWD 67.30 and its highest was TWD 93.70 in the past 12 months.
What is Foresee Pharmaceuticals Co., Ltd.’s market cap?
Foresee Pharmaceuticals Co., Ltd.’s market cap is TWD 11.33B.
When is Foresee Pharmaceuticals Co., Ltd.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Foresee Pharmaceuticals Co., Ltd.’s earnings last quarter?
Foresee Pharmaceuticals Co., Ltd. released its earnings results on Aug 13, 2026. The company reported -TWD 0.789 earnings per share for the quarter.
Is Foresee Pharmaceuticals Co., Ltd. overvalued?
Not enough analysts have published a price target to calculate whether the price is overvalued.
Does Foresee Pharmaceuticals Co., Ltd. pay dividends?
Foresee Pharmaceuticals Co., Ltd. does not currently pay dividends.
What is Foresee Pharmaceuticals Co., Ltd.’s EPS estimate?
Foresee Pharmaceuticals Co., Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Foresee Pharmaceuticals Co., Ltd. have?
Foresee Pharmaceuticals Co., Ltd. has 157,540,540 shares outstanding.
What happened to Foresee Pharmaceuticals Co., Ltd.’s price movement after its last earnings report?
Foresee Pharmaceuticals Co., Ltd. reported an EPS of -TWD 0.789 in its last earnings report. Following the earnings report the stock price went down -1.507%.
Which hedge fund is a major shareholder of Foresee Pharmaceuticals Co., Ltd.?
Currently, no hedge funds are holding shares in TW:6576
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Foresee Pharmaceuticals Co., Ltd.
Foresee is a Taiwan and US-based biopharmaceutical company focused on two key areas: its unique Stabilized Injectable Formulation (SIF) long-acting injectable technology with derived drug products for specialty markets, and its transformative preclinical and clinical first-in-class New Chemical Entity (NCE) programs targeting rare and severe disease areas with high unmet needs. Its product portfolio includes late and early-stage programs, with its lead product CAMCEVI® used for the treatment of advanced prostate cancer.